Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations

British Journal of Anaesthesia

Volumn 101, Issue 6, 2008, Pages 769-773

  Fenger Eriksen, C ^a   Lindberg Larsen, M ^a   Christensen, A Q ^a   Ingerslev, J ^a   Sorensen B ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Blood, coagulation; Blood, transfusion; Complications, coagulopathy; Drug delivery; Safety, drug

Indexed keywords

D DIMER; FIBRINOGEN; FRESH FROZEN PLASMA; HAEMOCOMPLETTAN; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; ERYTHROCYTE COUNT; FEMALE; HUMAN; HYPOFIBRINOGENEMIA; INFANT; MALE; OFF LABEL DRUG USE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SUBSTITUTION THERAPY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 56449111400     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen270     Document Type: Article

References (17)

1. Hardy JF, de Moerloose P, Samama CM. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2006; 53: S40-58
2. Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J Anaesth 2005; 95: 130-9
3. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-5
4. Fenger-Eriksen C, Anker-Moller E, Heslop J, et al. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005; 94: 324-9
5. De Lorenzo C, Calatzis A, Welsch U, et al. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg 2006; 102: 1194-200
6. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy - a porcine model. Br J Anaesth 2006; 97: 460-7
7. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma 2006; 60: S51-8
8. Ingerslev J, Sorensen B. Fibrinogen substitution. Use in the treatment of bleeding due to lack of fibrinogen. Ugeskr Laeger 2005; 167: 2759-61
9. Parasnis H, Raje B, Hinduja IN. Relevance of plasma fibrinogen estimation in obstetric complications. J Postgrad Med 1992; 38: 183-5
10. Nielsen VG, Levy JH. Fibrinogen and bleeding: old molecule - new ideas. Anesth Analg 2007; 105: 902-3
11. Summary of Product Characteristics (SPC) Haemocomplettanw. Available from http://www.anesthesia.at/zlbbehring/929395_F_FI_07-02- 15_Haemocomplettan%20CSL%20Behring.pdf
12. Danes AF, Cuenca LG, Bueno SR, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94: 221-6
13. Hiippala ST. Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 1995; 6: 743-6
14. Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107: S53-7
15. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101-7
16. Brandsborg S, Sorensen B, Poulsen LH, et al. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Blood Coagul Fibrinolysis 2006; 17: 241-9
17. Watanabe T, Minakami H, Sakata Y, et al. Effect of labor on maternal dehydration, starvation, coagulation, and fibrinolysis. J Perinat Med 2001; 29: 528-34